TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03207698

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement (OFD)
Description: Open flap debridement (OFD) alone

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)
Description: Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
Study: NCT04128969

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CS-
Description: Placebo
Study: NCT04336319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation
Description: 1. At baseline, the fecal fluid from 3 different donors, 150 ml, will be delivered via pouchoscopy after which the patient will roll in to the right lateral position and stay in that position for at least 15 minutes. Prior to the procedure, the patient will fast for 12 hours and preform two fleet enemas as preperation.~2. FMT at 7 days and 4 weeks will be delivered via ingestion of 15 capsules containing 650 µL of fecal fluid from 3 different donors (the same three donors as at baseline).
Study: NCT03207698

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OFD with Platelet rich fibrin (PRF)+1% Metformin (Drug) in gel form
Description: Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
Study: NCT00574626

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBSCT
Description: Peripheral Blood Stem Cell Transplant

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Transplant
Description: Bone Marrow Transplant
Study: NCT03433209

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ligasure device
Description: Vessel-sealing device used for laparoscopic hysterectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Articulating Enseal
Description: Vessel-sealing device used for laparoscopic hysterectomy
Study: NCT00287872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Study: NCT03305458

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TFCBT
Description: treatment as usual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eTFCBT
Description: tablet-facilitated Trauma Focused Cognitive Behavioral Therapy (eTFCBT)
Study: NCT02913404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Reconstruction
Description: standard surgical procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Recon. extra-articular-tenodesis
Description: standard surgical procedure and extra-articular-tenodesis will be used for a randomized portion of participants
Study: NCT03861702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: FOLFOX (Oxaliplatin, Leucovorin, 5-Fluorouracil)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan
Description: Liposomal Irinotecan
Study: NCT04519320

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pulmonary function testing
Description: D0: date of first symptoms of SARS-COV-2~M3: D0 + 3 months~* Blood test~* Blood gases~* Clinical examination~* CT Scan~* Pulmonary function testing (PFT)~* 6-minute walk test (6MWT)~* MOS SF-36 Questionnaire~* HADS scale~* Ventilatory polygraphy~M6: D0 + 6 months~* Clinical examination~* PFT~* 6MWT~* MOS SF-36 Questionnaire~* HADS scale~M12: D0 + 12 months~* Blood test~* Blood gases~* Clinical examination~* CT Scan (If anomaly found at M3)~* PFT~* Pulmonary Exercise Stress Test~* 6MWT~* MOS SF-36 Questionnaire~* HADS scale~Subsequent follow-up will be performed only in patients with an alteration defined by a DLCO \<LLN and / or an abnormality objectified at CT-Scan attributable to SARS-CoV-2.~M24, M36, M48 and M60: D0 + 24, 36, 48, 60 months~* Clinical examination~* PFT~* 6MWT~* MOS SF-36 Questionnaire~* HADS scale
Study: NCT03467061

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate-rich beetroot juice
Description: concentrated beetroot juice

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-depleted beetroot juice
Description: concentrated beetroot juice

Intervention type: OTHER
Group type: OTHER
Intervention: Mouthwash
Description: 2 x 10 mL antibacterial mouthwash per day for 14 days
Study: NCT00555919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonaprisan (ZK 230211, BAY86-5044)
Description: 25 mg daily oral treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lonaprisan (ZK 230211, BAY86-5044)
Description: 100 mg daily oral treatment
Study: NCT00832845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBSST plus treatment as usual
Description: Patients will receive CBSST in addition to their regular treatment for 36 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Patients will receive their regular treatment for 36 weeks without CBSST. TAU consists of the standard care that patients receive, including routine visits and contacts with their physicians and clinicians.
Study: NCT00020943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 5 ug/kg subQ daily day 4 until ANC \>10,000 (or ANC\> 5000 2X)Tx 1, 2, 4 10 ug/kg subQ daily day 14 until completion of PBSC collection Tx 3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/sq m IV infusion at , or = 400 mg/hr day 1 Tx 1, 2, days 5 \& 12 Tx 3, and weekly for 2 doses Tx 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: 15 mg/kg IV infusion over 2 hours Day 6, Tx 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 2000 mg/sq m IV infusion over 2 hours Day 3, Tx 1 \& 2 100 mg/kg IV infusion over 2 hours Day 2, Tx 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 2000 mg/sq m IV infusion BID over 2 hours x 8 doses Days 1-4, Tx 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 50 mg/sq m IVP Day 3, Tx 1\& 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 40 mg/kg total dose continuous IV infusion over 96 hours Days 1-4, Tx 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: 50 mg/sq m IV infusion q 6 hours x 3 doses after MTX, then 10 mg/sq m IV/PO q 6 hrs until MTX levels \<0.05 uM, Tx 1 \& 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 300 mg/sq m IV infusion over 4 hrs Day 2 Tx 1 \& 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 100 mg/sq m PO Days 3-7, Tx 1 \& 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.4 mg/sq m IVP Day 3, Tx 1 \& 2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Stem cells collected during Tx 3 will be transfused follwing chemotx in Tx 4
Study: NCT00856869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
Study: NCT01297439

Intervention type: PROCEDURE
Group type: OTHER
Intervention: suctioning of fetal nose and mouth during delivery
Description: Normal delivery without pushing maneuver: either an expectative attitude or a suctioning of fetal nose and mouth during delivery, since the crowning of the head (appearance of the fetal scalp at the introitus between pushes).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pushing maneuver
Description: The pushing maneuver is performed gently on the fetal head since the crowning of the head (appearance of the fetal scalp at the introitus between pushes), during one uterine contraction, aiming to facilitate the anterior shoulder to slip off behind the symphysis pubis, reducing thus the risk of shoulder dystocia.
Study: NCT03384836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Given PO
Study: NCT03718481

Intervention type: OTHER
Intervention: ARCP Process
Description: One Annual Review of Competence Progression (ARCP) cycle. In the U.K., doctors, across all specialities, undergo an Annual Review of Competence Progression (ARCP) to evaluate performance during each training year and determine progression to the next year of training. Similar processes exist in the Republic of Ireland. The process and requirements for ARCP in the UK are specified in the Gold Guide, the Reference Guide for Postgraduate Specialty Training \[1\]. It defines ARCP as a formal process that uses evidence collected by trainees to review and record performance, demonstrate competencies achieved and inform decisions regarding progression in training
Study: NCT04081025

Intervention type: OTHER
Intervention: EpiWux
Description: A cross-sectional and longitudinal study including a questionnaire and a clinical examination
Study: NCT00611949

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Geranium oil
Description: 2 applications of topical oil per week for 2 weeks
Study: NCT01598298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study: NCT02601937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
Study: NCT04701229

Intervention type: GENETIC
Intervention: somatic cytogenetic and genetic characterization
Description: investigating the presence of some genes allelles (RBM22, SLU7, RBM27, other on chromosome 5) by FISH, and sequencing of a classical panel of myeloid genes including RBM22, SLU7, for somatic identification of genetic alterationss of the blasts.

Intervention type: GENETIC
Intervention: somatic cytogenetic and genetic characterization
Description: investigating the presence of some genes allelles (RBM22, SLU7, RBM27, other on chromosome 5) by FISH, and sequencing of a classical panel of myeloid genes including RBM22, SLU7, for somatic identification of genetic alterationss of the blasts.
Study: NCT02601937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
Study: NCT02272309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG and EP measurement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG and EP measurement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG and EP measurement
Study: NCT04701229

Intervention type: GENETIC
Intervention: somatic cytogenetic and genetic characterization
Description: investigating the presence of some genes allelles (RBM22, SLU7, RBM27, other on chromosome 5) by FISH, and sequencing of a classical panel of myeloid genes including RBM22, SLU7, for somatic identification of genetic alterationss of the blasts.

Intervention type: GENETIC
Intervention: somatic cytogenetic and genetic characterization
Description: investigating the presence of some genes allelles (RBM22, SLU7, RBM27, other on chromosome 5) by FISH, and sequencing of a classical panel of myeloid genes including RBM22, SLU7, for somatic identification of genetic alterationss of the blasts.

Intervention type: GENETIC
Intervention: somatic cytogenetic and genetic characterization
Description: investigating the presence of some genes allelles (RBM22, SLU7, RBM27, other on chromosome 5) by FISH, and sequencing of a classical panel of myeloid genes including RBM22, SLU7, for somatic identification of genetic alterationss of the blasts.
Study: NCT03783403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-95251
Description: Specified dose on specified days
Study: NCT02954796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD352A
Description: On the first day of each 28-day cycle, SGN-CD352A will be given IV. The dose of SGN-CD352A is different in each cohort of the study, with the lowest dose in Cohort -1 (4 mcg/kg) and the highest in Cohort 6 (65 mcg/kg). Patients can only be enrolled into a higher dose level arm if lower doses have proven safe.
Study: NCT03783403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-95251
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-95251
Description: Specified dose on specified days
Study: NCT06741124

Intervention type: PROCEDURE
Intervention: Channel Esophagogastrostomy
Description: Channel Esophagogastrostomy

Intervention type: PROCEDURE
Intervention: Double Tract Reconstruction
Description: Double Tract Reconstruction
Study: NCT06755164

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simultaneous aerobic and cognitive training (SIM)
Description: The SIMULTANEOUS Group (SIM) will undergo15 minutes of stretching and preparatory mobilization + 40 minutes of cyclette (5 minutes warm-up, 30 minutes aerobic and cognitive training, 5 minutes cool-down) + 15 minutes of mobilization and deep breathing (total: 70 minutes). Patients will perform the cognitive training sited on the cyclette using an adapted computer screen and a joystick.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequential aerobic and cognitive training (SEQ)
Description: The SEQUENTIAL Group (SEQ) will undergo 40 minutes of cyclette (5 minutes warm-up, 30 minutes aerobic training, 5 minutes cool-down), + 30 minutes of cognitive training (total: 70 minutes). Patients will perform the cognitive training after the aerobic training, sited on a desk using a computer and a joystick.
Study: NCT06766708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-management lymphedema (SML) education program
Description: The content of the booklet was prepared based on literature review.. In addition to the above intervention methods, the phone number of each patient was taken and the patients were followed up by phone for 12 months. For this purpose, the patient was asked to fill in the compliance chart prepared in order to monitor the patient's compliance and was checked by the researcher every two weeks by phone call. By phone call; compliance with skin care, SLD, compression garments and exercise practices included in the SMLEP were evaluated and recorded. Within the scope of the SMLEP, the patients were asked to do exercises and SLD at least 3 days a week and 2 times a day (morning and evening) for 12 months. It was recommended to wear compression garments, especially during exercises and throughout the day.
Study: NCT03783403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Specified dose on specified days
Study: NCT01343277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Type=exactly number, unit=mg/m2, number=1.5, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Type=exactly number, unit=g/m2, number=1, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
Study: NCT00342381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3,4-diaminopyridine
Description: Single dose 3,4 diaminopyridine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose placebo treatment
Study: NCT03193112

Intervention type: DRUG
Intervention: Agomelatine 25 MG Oral Tablet
Description: We will treat our patients with Agomelatine tablet of 25 mg.
Study: NCT01068886

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External pancreatic stent
Description: stent through pancreatic anastomosis
Study: NCT01881204

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hesperidin and Calcilock
Description: Hesperidin (552mg) and Calcilock® (amount per day: Calcium: 684 mg; Phosphorus: 282mg; Magnesium: 102mg; Zinc: 2.86mg; Vitamin C: 20 mg; Vitamin K1: 28µg; Vitamin D: 1.86µg) will be administered in the form of cookies (biscuit).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hesperidin
Description: Hesperidin (552mg) will be administered in the form of cookies (biscuit).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Cookies without Hesperidin or Calcilock added.
Study: NCT03132064

Intervention type: PROCEDURE
Intervention: total knee arthroplasty
Description: surgical repair for end stage of knee osteoarthritis.
Study: NCT05140629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baobab fruit aqueous extract
Description: After overnight fasting, blood glucose level was assessed through a capillary drop blood, immediately before Oral Glucose Tolerance Test (t0). The intervention group ingested glucose solution followed by 250 ml of baobab aqueous extract (33.33 g FW). Blood glucose level was also measured at 30 (t30), 60 (t60), 90 (t90) and 120 (t120) minutes immediately after intervention, for each participant, in control and intervention groups. Glucometer equipment, strips for glucose meters (One Touch Select Plus) and sterilized lancets (Sarstedt normal 21G) were used to measure blood glucose concentrations, taking due care of safety and asepsis.
Study: NCT01201603

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: orange juice
Description: 250ml of orange juice or a sugars matched orange drink

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: orange juice
Description: 250ml of orange juice or a sugars matched orange drink
Study: NCT00433615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R744
Description: 100μg(s.c./i.v.)/4 week for 8 weeks, then 25\~400μg(s.c./i.v.)/4 week for 40 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R744
Description: 150μg(s.c./i.v.)/4 week for 8 weeks, then 25\~400μg(s.c./i.v.)/4 week for 40 weeks
Study: NCT04112225

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Happify
Description: An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Happify
Description: An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
Study: NCT00284141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Description: Aflibercept 4.0 mg/kg administered intravenously (IV) over a period of at least 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level (to 3.0 mg/kg) or 2 dose levels (to 2.0 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment.
Study: NCT01090310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIN457
Description: AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to AIN457